PALISADE BIO, INC. Common Stock, Value, Issued
PALISADE BIO, INC. (PALI) had Common Stock, Value, Issued of $1.74 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-08-10
- 2026-06-30: Common Stock, Value, Issued $1.74M.
- 2026-03-31: Common Stock, Value, Issued $1.67M.
- 2025-12-31: Common Stock, Value, Issued $1.59M.
- 2025-09-30: Common Stock, Value, Issued $91.00K.
| Period end | Common Stock, Value, Issued | Common Stock, Value, Issued as first filed |
|---|---|---|
| 2026-06-30 | $1.74M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $1.67M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $1.59M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $91.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $48.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $43.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $27.00K 10-K · filed 2026-03-20 | |
| 2024-09-30 | $11.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $9.00K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $8.00K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $6.00K 10-K · filed 2025-03-24 | $93.00K 10-K · filed 2024-03-26 |
| 2023-09-30 | $92.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $69.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $46.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $30.00K 10-K · filed 2024-03-26 | |
| 2022-09-30 | $771.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $220.00K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $183.00K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $3.00K 10-K · filed 2023-03-22 | $143.00K 10-K · filed 2022-03-17 |
| 2021-09-30 | $130.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $114.00K 10-Q · filed 2021-08-23 | |
| 2021-03-31 | $28.83K 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $28.00K 10-K · filed 2022-03-17 | $172.96K 10-K · filed 2021-03-22 |
| 2020-09-30 | $172.96K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $172.96K 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $94.28K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $38.66K 10-K · filed 2021-03-22 | |
| 2019-09-30 | $28.18K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $10.02K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $182.05K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $9.10K 10-K · filed 2020-03-27 | $182.05K 10-K · filed 2019-03-22 |
| 2018-09-30 | $152.05K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $151.60K 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $151.60K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $151.60K 10-K · filed 2019-03-22 | |
| 2017-09-30 | $151.46K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $120.13K 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $117.43K 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $110.33K 10-K · filed 2018-04-02 | |
| 2016-09-30 | $1.15M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $1.15M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $920.44K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $70.77K 10-K · filed 2017-03-23 | $920.06K 10-K · filed 2016-03-14 |
| 2015-09-30 | $917.86K 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $903.60K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $903.37K 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $877.90K 10-K · filed 2016-03-14 | |
| 2014-09-30 | $871.56K 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $868.38K 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $866.89K 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $778.86K 10-K · filed 2015-03-16 | |
| 2013-09-30 | $766.63K 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $706.06K 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $687.98K 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $681.89K 10-K · filed 2014-03-10 | |
| 2012-09-30 | $679.64K 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $540.95K 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $540.62K 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $486.82K 10-K · filed 2013-03-15 | |
| 2011-09-30 | $486.82K 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $484.86K 10-Q/A · filed 2011-09-23 | |
| 2010-12-31 | $468.98K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |